Search / Trial NCT00000873

A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of October 22, 2024

Completed

Keywords

Nutritional Status Hiv Seronegativity Infant Food

Description

In order to meet the optimal nutritional needs of HIV-infected infants, it is critical that nutritional intervention begin early. Early nutritional intervention may help reduce the susceptibility to or severity of primary HIV and/or opportunistic infections and add to the quality of life for children perinatally infected with HIV. \[AS PER AMENDMENT 08/29/01: This study population will consist of infants from domestic sites and international sites.\] In this double-blind, controlled study perinatally HIV-exposed infants less than 15 days old \[AS PER AMENDMENT 08/29/01: "less than 15 days ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Children may be eligible for this study if they:
  • * Are 1 to 17 days old. (This study has been changed. Originally, infants 1 to 15 days old were eligible for this study.)
  • * Weigh 4 or more pounds.
  • * Were born to an HIV-positive mother.
  • * Have a caregiver willing to measure and keep records of infant's food intake.
  • Exclusion Criteria
  • Children will not be eligible for this study if they:
  • * Are breast-fed.
  • * Have certain disorders, including the inability to feed by mouth, or a life-threatening condition.
  • * Take medication which affects growth.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Los Angeles, California, United States

Springfield, Massachusetts, United States

Seattle, Washington, United States

Bronx, New York, United States

La Jolla, California, United States

Long Beach, California, United States

Los Angeles, California, United States

Los Angeles, California, United States

Los Angeles, California, United States

Denver, Colorado, United States

New Haven, Connecticut, United States

Washington, District Of Columbia, United States

Miami, Florida, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Baltimore, Maryland, United States

Baltimore, Maryland, United States

Boston, Massachusetts, United States

Detroit, Michigan, United States

New Brunswick, New Jersey, United States

Newark, New Jersey, United States

Albany, New York, United States

Brooklyn, New York, United States

Great Neck, New York, United States

New York, New York, United States

New York, New York, United States

New York, New York, United States

New York, New York, United States

New York, New York, United States

Stony Brook, New York, United States

Syracuse, New York, United States

Durham, North Carolina, United States

Columbus, Ohio, United States

Charleston, South Carolina, United States

Dallas, Texas, United States

Houston, Texas, United States

Bayamon, , Puerto Rico

San Juan, , Puerto Rico

San Juan, , Puerto Rico

Newark, New Jersey, United States

St Louis, Missouri, United States

Tampa, Florida, United States

Augusta, Georgia, United States

New Orleans, Louisiana, United States

Jacksonville, Florida, United States

Durham, North Carolina, United States

Rochester, New York, United States

Miami, Florida, United States

Birmingham, Alabama, United States

Mobile, Alabama, United States

Farmington, Connecticut, United States

Fort Lauderdale, Florida, United States

Gainesville, Florida, United States

Riviera Beach, Florida, United States

Jackson, Mississippi, United States

Camden, New Jersey, United States

Richmond, Virginia, United States

Phoenix, Arizona, United States

Columbus, Georgia, United States

New Brunswick, New Jersey, United States

Orlando, Florida, United States

Pensacola, Florida, United States

Columbia, South Carolina, United States

San Antonio, Texas, United States

Nassau, , Bahamas

Belo Horizonte Mg, , Brazil

Rio De Janeiro Rj, , Brazil

Rio De Janeiro, , Brazil

Caguas, , Puerto Rico

Mayguez, , Puerto Rico

Ponce, , Puerto Rico

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0